1. Pink Sheet

Public Citizen: US FDA Deliberately Excluded Risk Committee From Dsuvia Panel To Get Positive Vote

 
• By Michael Cipriano

Risk committee has joined nearly all opioid reviews over past few years but didn’t for AcelRx's sublingual product; Raeford Brown, the analgesic advisory committee chair who was unable to attend the meeting, voices his displeasure with the vote. 

AcelRx Pharmaceuticals Inc.'s sublingual opioid Dsuvia (sufentanil) made waves by becoming the first opioid in 2018 to get a positive vote from a US FDA advisory committee. But Public Citizen is alleging that agency deliberately decided not to convene the full Drug Safety and Risk Management Advisory Committee (DSRMAC) to help deliver a positive vote.

In a letter dated Oct

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers